Nahh, just remove them
First generation (methylation) aging clocks (2011) were developed after brain age (2010). The aging field has subsequently moved on and is now in its third or fourth generation. Yet, in the neuroimaging field, we are still stuck with brain age, essentially a first generation clock.
IMO there is no reason to rely on LLMs to generate citations. Overloaf integrates very well with Zotero and Mendeley, and if you use other editors, most reference managers export bibtex files. So why would I require an LLM to generate my citations.
After 5 years of data collection, our WARN-D machine learning competition to forecast depression onset is now LIVE! We hope many of you will participate—we have incredibly rich data.
If you share a single thing of my lab this year, please make it this competition.
eiko-fried.com/warn-d-machi...
I'm excited to share our pre-registered phase IIa pilot study on rapamycin treatment in early Alzheimer's disease, using multimodal neuroimaging and CSF biomarkers to assess safety and feasibility! doi.org/10.64898/202... (1/6)
Interestingly, levels of certain CSF biomarkers increased (total tau, neurofilament light, and Aβ40/42), while the p-tau/total tau ratio decreased. These unexpected findings warrant further investigation to determine their implications for drug administration and potential long-term effects. (6/6)
There was also a positive correlation between the drug's blood concentration and increased brain metabolism, although the sample size is small and definitive conclusions are difficult to draw. (5/6)
Rapamycin was well tolerated with no serious adverse events. Glucose metabolism in our primary regions showed no decline and perhaps even increased in exploratory regions, in contrast to what would be expected from the natural disease progression. (4/6)
We measured brain glucose metabolism using FDG PET, measured blood flow using ASL MRI, tested for CSF biomarkers, measured volumetric changes on MRI, and performed cognitive assessments before and after treatment. (3/6)
Rapamycin is a well-known putative geroprotective compound that extends life- and healthspan in preclinical models, but human clinical data remain limited. In this study, we enrolled 14 participants with early Alzheimer’s disease who received a weekly dose of oral rapamycin for 26 weeks. (2/6)
I'm excited to share our pre-registered phase IIa pilot study on rapamycin treatment in early Alzheimer's disease, using multimodal neuroimaging and CSF biomarkers to assess safety and feasibility! doi.org/10.64898/202... (1/6)
When you can't give a simple answer to that question... something needs to be redesigned! I have never seen a conference need to make a video to explain *character limits*. 🤔
@euripsconf.bsky.social
Love it EurIPA #EurIPS
I think that many people interested in explainable/interpretable "AI" in medicine and health mean well but misunderstand the nature and value of prediction. This focus, imo, is also a distraction from much more needed efforts to ensure that AI based predictions are actually useful.
No hand-drawn slides? ;D
A lot of crap research is being done with the microbiome. At the heart of much of the research is fundamentally unreliable data.
More open journals like TMLR. IMO the peer review process is much better anyway.
Alt.
Not surprising, as both are on that paper as well :D
Very much in line with work by Vidal-Pineiro et al., 2021 (eLife) and Smith et al., 2025 (Imaging Neuroscience).
Interesting paper showing that "much inter-individual differences in neuroanatomical volumes almost exclusively reflects stable differences between individuals" before 60 years, rather than age-related changes.
www.biorxiv.org/content/10.1...
Prompt to Chat: "Please explain [insert methodology] to me like I'm 10 years old and stupid"
Issue 3: "While cross-sectional studies can provide valuable snapshots of developmental differences, they are insufficient for testing hypotheses about the speed, timing, or trajectory of brain development"
Issue 1: "Existing research has not established what degree of variability in BAG is typical, and what may reflect substantially accelerated or decelerated development"
Pretty good perspective paper on brain age in kids:
www.nature.com/articles/s41...
I think a lot of the points / issues are relevant to the entire field, not only brain age in younger populations.
Pretty cool development! New high-res neuro-PET scanner. Look at the cortical ribbon and the small subcortical regions and nuclei!
link.springer.com/article/10.1...
Registration opened just 1 week ago and we already have 390+ registrations from more than 25 countries and presenting 85+ papers! We are very excited to see the community support the #EurIPS initiative and look forward to meeting you all in Copenhagen 🙌
Congratulations to everyone who got their @neuripsconf.bsky.social papers accepted 🎉🎉🎉
At #EurIPS we are looking forward to welcoming presentations of all accepted NeurIPS papers, including a new “Salon des Refusés” track for papers which were rejected due to space constraints!
Exactly! EurIPS just announced that they will accept submission of those rejected papers.
